A detailed history of Orbimed Advisors LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Orbimed Advisors LLC holds 766,906 shares of CYTK stock, worth $38.5 Million. This represents 0.95% of its overall portfolio holdings.

Number of Shares
766,906
Previous 812,906 5.66%
Holding current value
$38.5 Million
Previous $44 Million 8.06%
% of portfolio
0.95%
Previous 1.06%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$51.22 - $60.16 $2.36 Million - $2.77 Million
-46,000 Reduced 5.66%
766,906 $40.5 Million
Q2 2024

Aug 14, 2024

BUY
$47.86 - $75.05 $6.23 Million - $9.77 Million
130,206 Added 19.07%
812,906 $44 Million
Q1 2024

May 15, 2024

BUY
$63.75 - $108.06 $43.5 Million - $73.8 Million
682,700 New
682,700 $47.9 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.73B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.